• Consensus Rating: Moderate Buy
  • Consensus Price Target: $259.00
  • Forecasted Upside: 40.27%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$184.65
▼ -1.82 (-0.98%)

This chart shows the closing price for TFX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Teleflex Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TFX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TFX

Analyst Price Target is $259.00
▲ +40.27% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Teleflex in the last 3 months. The average price target is $259.00, with a high forecast of $290.00 and a low forecast of $227.00. The average price target represents a 40.27% upside from the last price of $184.65.

This chart shows the closing price for TFX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 8 investment analysts is to moderate buy stock in Teleflex. This rating has held steady since October 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 0 sell ratings
6/17/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 7 hold ratings
  • 0 sell ratings
9/15/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
12/14/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
3/13/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/11/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/9/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
11/8/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/8/2024

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/4/2024Truist FinancialReiterated RatingHold ➝ Hold$255.00 ➝ $227.00
11/1/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$275.00 ➝ $245.00
11/1/2024MizuhoLower TargetNeutral ➝ Neutral$275.00 ➝ $250.00
11/1/2024Needham & Company LLCReiterated RatingHold
10/14/2024Truist FinancialBoost TargetHold ➝ Hold$247.00 ➝ $255.00
10/8/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$260.00 ➝ $275.00
8/5/2024Truist FinancialBoost TargetHold ➝ Hold$240.00 ➝ $247.00
8/2/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$235.00 ➝ $260.00
8/2/2024StephensBoost TargetOverweight ➝ Overweight$275.00 ➝ $290.00
7/16/2024Truist FinancialBoost TargetHold ➝ Hold$235.00 ➝ $240.00
7/9/2024Truist FinancialBoost TargetHold ➝ Hold$219.00 ➝ $235.00
7/1/2024Piper SandlerUpgradeNeutral ➝ Overweight$205.00 ➝ $245.00
5/3/2024Truist FinancialLower TargetHold ➝ Hold$240.00 ➝ $219.00
5/3/2024Needham & Company LLCReiterated RatingHold
2/23/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$285.00
2/23/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$272.00 ➝ $265.00
2/23/2024Truist FinancialLower TargetHold ➝ Hold$270.00 ➝ $265.00
1/12/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$228.00 ➝ $272.00
12/22/2023Truist FinancialBoost TargetHold ➝ Hold$221.00 ➝ $270.00
12/20/2023Raymond JamesBoost TargetOutperform ➝ Outperform$227.00 ➝ $271.00
12/4/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight$261.00
11/6/2023Piper SandlerBoost TargetNeutral ➝ Neutral$210.00 ➝ $225.00
11/6/2023Truist FinancialBoost TargetHold ➝ Hold$210.00 ➝ $221.00
11/3/2023JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$315.00 ➝ $285.00
11/3/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$218.00 ➝ $228.00
11/3/2023StephensReiterated RatingOverweight ➝ Overweight$275.00
10/11/2023StephensReiterated RatingOverweight ➝ Overweight$315.00
8/7/2023Truist FinancialLower TargetHold ➝ Hold$264.00 ➝ $255.00
8/7/2023Raymond JamesLower TargetOutperform ➝ Outperform$272.00 ➝ $255.00
8/4/2023JMP SecuritiesLower TargetOutperform ➝ Outperform$330.00 ➝ $315.00
7/27/2023StephensBoost Target$305.00 ➝ $315.00
7/19/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$261.00
6/21/2023Needham & Company LLCDowngradeBuy ➝ Hold
5/30/2023CL KingInitiated CoverageBuy$293.00
4/26/2023Wolfe ResearchDowngradeOutperform ➝ Peer Perform
4/18/2023MizuhoBoost Target$220.00 ➝ $250.00
4/17/2023Truist FinancialBoost TargetHold$250.00 ➝ $264.00
3/30/2023JMP SecuritiesReiterated RatingMarket Outperform$330.00
2/27/2023Truist FinancialLower TargetHold$260.00 ➝ $250.00
2/24/2023Needham & Company LLCReiterated RatingBuy$291.00
2/24/2023Raymond JamesBoost TargetOutperform$231.00 ➝ $259.00
1/31/2023Truist FinancialLower TargetHold$272.00 ➝ $260.00
1/6/2023Morgan StanleyBoost TargetEqual Weight$236.00 ➝ $280.00
12/28/2022StephensBoost TargetOverweight$280.00 ➝ $295.00
12/20/2022Truist FinancialBoost TargetHold$225.00 ➝ $272.00
10/28/2022Raymond JamesLower TargetOutperform$266.00 ➝ $231.00
10/28/2022Royal Bank of CanadaLower TargetOutperform$342.00 ➝ $308.00
10/28/2022StephensLower TargetOverweight$305.00 ➝ $280.00
10/28/2022Wells Fargo & CompanyLower TargetEqual Weight$248.00 ➝ $229.00
10/28/2022Truist FinancialBoost TargetHold$220.00 ➝ $225.00
10/28/2022JMP SecuritiesLower TargetMarket Outperform$370.00 ➝ $330.00
10/27/2022Piper SandlerLower Target$265.00 ➝ $245.00
10/26/2022MizuhoInitiated CoverageNeutral$220.00
10/13/2022StephensInitiated CoverageOverweight$305.00
10/12/2022Jefferies Financial GroupInitiated CoverageHold$210.00
10/11/2022Morgan StanleyLower TargetEqual Weight$278.00 ➝ $236.00
9/22/2022Truist FinancialLower TargetHold$265.00 ➝ $241.00
7/29/2022Morgan StanleyLower TargetEqual Weight$300.00 ➝ $278.00
7/29/2022Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$248.00
7/28/2022Piper SandlerLower Target$295.00 ➝ $265.00
7/22/2022Truist FinancialLower Target$270.00
7/15/2022Morgan StanleyLower TargetEqual Weight$343.00 ➝ $300.00
7/5/2022Wolfe ResearchInitiated CoverageOutperform$300.00
5/23/2022Truist FinancialLower TargetHold$340.00 ➝ $317.00
5/23/2022Royal Bank of CanadaLower Target$390.00 ➝ $380.00
5/9/2022Bank of AmericaInitiated CoverageNeutral$315.00
4/29/2022Truist FinancialLower Target$370.00 ➝ $340.00
4/12/2022Truist FinancialInitiated CoverageHold$370.00
2/25/2022Morgan StanleyLower TargetEqual Weight$383.00 ➝ $378.00
2/24/2022Piper SandlerBoost Target$320.00 ➝ $335.00
2/23/2022Raymond JamesLower TargetOutperform$391.00 ➝ $370.00
1/31/2022Needham & Company LLCLower TargetBuy$425.00 ➝ $400.00
1/21/2022Piper SandlerLower Target$325.00 ➝ $320.00
1/7/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$431.00 ➝ $383.00
1/4/2022Piper SandlerDowngradeOverweight ➝ Neutral$465.00 ➝ $325.00
12/13/2021Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$450.00 ➝ $355.00
12/9/2021Royal Bank of CanadaInitiated CoverageOutperform$415.00
10/29/2021Morgan StanleyLower TargetOverweight$478.00 ➝ $431.00
10/29/2021Raymond JamesLower TargetOutperform$440.00 ➝ $391.00
10/29/2021JMP SecuritiesLower TargetMarket Outperform$470.00 ➝ $430.00
9/10/2021Jefferies Financial GroupInitiated CoverageBuy$485.00
9/7/2021Raymond JamesInitiated CoverageBuy$440.00
8/2/2021KeyCorpLower TargetOverweight$448.00 ➝ $439.00
7/30/2021JMP SecuritiesReiterated RatingMarket Outperform
7/30/2021Leerink PartnersBoost TargetMarket Perform$410.00 ➝ $415.00
7/19/2021Leerink PartnersDowngradeOutperform ➝ Market Perform$485.00 ➝ $410.00
7/9/2021Needham & Company LLCInitiated CoverageBuy$486.00
6/2/2021Jefferies Financial GroupReiterated RatingBuy$485.00
5/23/2021Leerink PartnersReiterated RatingBuy
4/30/2021Morgan StanleyBoost TargetOverweight$450.00 ➝ $478.00
4/30/2021Leerink PartnersBoost TargetOutperform$475.00 ➝ $485.00
3/12/2021Raymond JamesBoost TargetStrong-Buy$460.00 ➝ $480.00
2/26/2021Raymond JamesBoost TargetStrong-Buy$440.00 ➝ $460.00
2/25/2021Piper SandlerReiterated RatingOverweight$405.00 ➝ $465.00
1/27/2021JMP SecuritiesBoost TargetMarket Outperform$375.00 ➝ $440.00
1/11/2021Wells Fargo & CompanyBoost TargetOverweight$425.00 ➝ $455.00
1/8/2021KeyCorpBoost TargetOverweight$382.00 ➝ $441.00
1/6/2021Needham & Company LLCBoost TargetBuy$406.00 ➝ $445.00
12/15/2020Morgan StanleyBoost TargetOverweight$375.00 ➝ $450.00
12/15/2020UBS GroupBoost TargetBuy$435.00 ➝ $455.00
12/15/2020Leerink PartnersBoost TargetOutperform$415.00 ➝ $450.00
12/3/2020Raymond JamesBoost TargetStrong-Buy$400.00 ➝ $440.00
11/2/2020KeyCorpUpgradeSector Weight ➝ Overweight$382.00
10/30/2020Piper SandlerLower Target$420.00 ➝ $405.00
10/30/2020Morgan StanleyLower TargetOverweight$400.00 ➝ $375.00
10/30/2020Raymond JamesLower TargetStrong-Buy$440.00 ➝ $400.00
10/30/2020Leerink PartnersLower TargetOutperform$430.00 ➝ $415.00
8/28/2020Raymond JamesReiterated RatingBuy
7/31/2020Raymond JamesBoost TargetStrong-Buy$400.00 ➝ $440.00
7/31/2020Morgan StanleyBoost TargetOverweight$380.00 ➝ $400.00
6/4/2020Leerink PartnersBoost TargetTop Pick ➝ Outperform$400.00 ➝ $425.00
5/1/2020UBS GroupLower TargetBuy$440.00 ➝ $410.00
5/1/2020JMP SecuritiesLower TargetMarket Outperform$395.00 ➝ $385.00
5/1/2020Wells Fargo & CompanyBoost TargetOverweight$365.00 ➝ $375.00
5/1/2020Morgan StanleyBoost TargetOverweight$350.00 ➝ $380.00
5/1/2020Raymond JamesBoost TargetStrong-Buy$360.00 ➝ $400.00
5/1/2020Piper SandlerLower TargetOverweight$425.00 ➝ $375.00
4/30/2020Needham & Company LLCReiterated RatingBuy$431.00
4/3/2020Raymond JamesLower TargetStrong-Buy$450.00 ➝ $360.00
3/27/2020Morgan StanleyLower TargetOverweight$405.00 ➝ $350.00
3/23/2020StephensLower TargetOverweight$425.00 ➝ $275.00
2/24/2020BarclaysReiterated RatingHold$365.00 ➝ $378.00
2/21/2020Piper SandlerBoost Target$425.00 ➝ $400.00
2/21/2020StephensBoost TargetOverweight$400.00 ➝ $425.00
2/21/2020Raymond JamesBoost TargetStrong-Buy$415.00 ➝ $450.00
2/21/2020UBS GroupBoost TargetBuy$430.00 ➝ $440.00
1/31/2020Needham & Company LLCBoost TargetBuy$408.00 ➝ $423.00
1/17/2020Wells Fargo & CompanyBoost TargetOverweight$415.00 ➝ $425.00
12/18/2019UBS GroupBoost TargetBuy$415.00 ➝ $430.00
12/17/2019Morgan StanleyBoost TargetOverweight$392.00 ➝ $405.00
(Data available from 12/8/2019 forward)

News Sentiment Rating

1.05 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 21 very positive mentions
  • 23 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/12/2024
  • 22 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
6/11/2024
  • 5 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/11/2024
  • 20 very positive mentions
  • 24 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/10/2024
  • 19 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/9/2024
  • 26 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/9/2024
  • 22 very positive mentions
  • 32 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
11/8/2024
  • 27 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
12/8/2024

Current Sentiment

  • 27 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Teleflex logo
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
Read More

Today's Range

Now: $184.65
Low: $184.23
High: $188.60

50 Day Range

MA: $214.17
Low: $184.65
High: $247.32

52 Week Range

Now: $184.65
Low: $184.23
High: $257.85

Volume

270,563 shs

Average Volume

461,568 shs

Market Capitalization

$8.58 billion

P/E Ratio

36.71

Dividend Yield

0.73%

Beta

1.16

Frequently Asked Questions

What sell-side analysts currently cover shares of Teleflex?

The following Wall Street sell-side analysts have issued reports on Teleflex in the last twelve months: JMP Securities, Mizuho, Needham & Company LLC, Piper Sandler, Raymond James, Royal Bank of Canada, Stephens, StockNews.com, and Truist Financial Co..
View the latest analyst ratings for TFX.

What is the current price target for Teleflex?

0 Wall Street analysts have set twelve-month price targets for Teleflex in the last year. Their average twelve-month price target is $259.00, suggesting a possible upside of 40.3%. Stephens has the highest price target set, predicting TFX will reach $290.00 in the next twelve months. Truist Financial Co. has the lowest price target set, forecasting a price of $227.00 for Teleflex in the next year.
View the latest price targets for TFX.

What is the current consensus analyst rating for Teleflex?

Teleflex currently has 3 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for TFX.

What other companies compete with Teleflex?

Other companies that are similar to Teleflex include ResMed, IDEXX Laboratories, DexCom, STERIS and Insulet. Learn More about companies similar to Teleflex.

How do I contact Teleflex's investor relations team?

Teleflex's physical mailing address is 550 E SWEDESFORD RD, WAYNE PA, 19087. The medical technology company's listed phone number is (610) 225-6800 and its investor relations email address is [email protected]. The official website for Teleflex is www.teleflex.com. Learn More about contacing Teleflex investor relations.